In this study, we aimed to investigate the relationships between sleep duration and autonomic nervous system (ANS) regulation. This cross-sectional pilot study included 27 older patients with probable Alzheimer’s disease who were hospitalized at a psychiatric center. We measured heart rate variability to assess ANS regulation at night, evaluated dementia severity via the Clinical Dementia Rating scale, and obtained sleep duration data from sleep diaries maintained by psychiatric nurses. The data were analyzed using repeated-measures generalized linear models with age, sex, dementia severity, hypertension status, and medication use (antipsychotics) as covariates. A sleep duration of 6–9 h per night compared to shorter than 6 h was associated with a greater increase in parasympathetic nervous system activity (p = 0.03), and a sleep duration longer than 9 h was associated with a decrease sympathovagal balance (p = 0.02). In addition, we observed an inverted U-shaped association between sleep duration and ANS regulation. In this pilot study, we demonstrated that a sleep duration of 6–9 h per night may be beneficial for ANS regulation; however, the present study involved only a few participants and had some limitations. Additional research with a larger cohort is needed to confirm these findings.

Low-color-temperature candlelight organic light-emitting diodes (OLEDs) offer a healthier lighting alternative by minimizing blue light exposure, which is known to disrupt circadian rhythms, suppress melatonin, and potentially harm the retina with prolonged use. In this study, we explore the integration of transition metal dichalcogenides (TMDs), specifically molybdenum disulfide (MoS₂) and tungsten disulfide (WS₂), into the hole injection layers (HILs) of OLEDs to enhance their performance. The TMDs, which are known for their superior carrier mobility, optical properties, and 2D layered structure, were doped at levels of 0%, 5%, 10%, and 15% in PEDOT:PSS-based HILs. Our findings reveal that OLEDs doped with 10% MoS₂ exhibit notable enhancements in power efficacy (PE), current efficacy (CE), and external quantum efficiency (EQE) of approximately 39%, 21%, and 40%, respectively. In comparison, OLEDs incorporating 10% of WS₂ achieve a PE of 28%, a CE of 20%, and an EQE of 35%. The enhanced performance of the MoS₂-doped devices is attributed to their superior hole injection and balanced carrier transport properties, resulting in more efficient operation. These results highlight the potential of incorporating 2D TMDs, especially MoS₂, into OLED technology as a promising strategy to enhance energy efficiency. This approach aligns with environmental, social, and governance (ESG) goals by emphasizing reduced environmental impact and promoting ethical practices in technology development. The improved performance metrics of these TMD-doped OLEDs suggest a viable path towards creating more energy-efficient and health-conscious lighting solutions.

Purpose This study evaluated the feasibility and preliminary effects of body–mind–spirit (BMS) group therapy—integrating Eastern gratitude philosophies with Western psychotherapy—on sleep and quality of life (QoL) among adults with visual impairment (VI). Methods A quasi-experimental study recruited 30 adults with VI (mean age 61.5 ± 11.4 years, range 26–78; 53.3% female). The experimental group received 10 weekly 130-min BMS sessions; the control group received usual care. QoL was assessed using the WHOQOL-BREF, and sleep was measured through accelerometry (XA-5) and self-reports. Results Compared with the comparison group, the intervention group showed significant improvements in overall QoL (p = 0.01, d = 0.58), with the most robust effect observed in physical health (d = 0.71). While objective sleep metrics remained statistically unchanged, the experimental group reported moderate improvements in sleep latency (d = −0.32; 23% reduction) and increased satisfaction. Data stability was influenced by a perceived lack of security in wearable devices. Notably, longer sleep duration correlated with better psychological well-being (p = 0.01), while lower gains among younger participants were linked to significantly shorter baseline sleep duration associated with their occupations. Conclusion BMS therapy is feasible and may enhance QoL and subjective sleep through improved emotional regulation. Although “circadian hardwiring” may limit physiological reset, BMS offers a psychological buffer against sleep dissatisfaction. Future trials should integrate circadian-focused strategies and address cultural conservatism regarding sensitive QoL dimensions. Trial registration IRB of Taipei City Hospital (TCHIRB-11107010); ClinicalTrials.gov (NCT07105761); Registration date: 13 August 2025.

Semiconductor manufacturing relies on specialized yellow lighting in lithography fabs to prevent photoresist degradation, but such artificial lighting may raise concerns regarding human health and ESG goals. This study evaluates whether natural light-style candlelight can replace conventional yellow lighting while remaining photoresist- and human-friendly. We compare the two lighting conditions from fabrication, retinal, physiological, psychological, concentration, and visual perspectives. The findings provide seven reasons supporting candlelight: it better prevents photoresist degradation, reduces retinal stress, causes less melatonin suppression, improves reported comfort and psychological well-being, maintains working concentration, and provides favorable viewing clarity and ocular responses. Its chromaticity is also closer to the blackbody radiation locus, supporting a more natural lighting environment. These results indicate that blue-less candlelight-style illumination can satisfy key lithography-lighting requirements while supporting worker well-being. The proposed transition may therefore contribute to healthier and more sustainable semiconductor manufacturing environments and offers broader relevance to healthcare, education, architecture, and interior lighting applications.

This study aimed to investigate the relationship between sleep duration, dementia severity, age, and ANS regulation. This cross-sectional pilot study included 27 older patients with probable Alzheimer’s disease, hospitalized at a psychiatric center. We measured heart rate variability to assess ANS regulation at night, evaluated dementia severity using the Clinical Dementia Rating scale, and obtained sleep duration data from sleep diaries maintained by psychiatric nurses. The data were analyzed using repeated-measures generalized linear models with age, sex, dementia severity, and medication (antipsychotics) as covariates. A sleep duration of 7–8 h per night was associated with better ANS regulation than other sleep durations, as indicated by sympathovagal balance (p = 0.005). ANS dysregulation was characterized by a 20.7% increase in sympathetic nervous system activity and a 14.8% decrease in parasympathetic nervous system (PSNS) activity. We found a significant correlation between dementia severity and PSNS activity (p = 0.04) and observed an inverted U-shaped association between sleep duration and ANS regulation. This pilot study demonstrated that a sleep duration of 7–8 h per night may be critical in maintaining optimal ANS regulation. Bidirectional associations between sleep duration, inadequate sleep duration, aging, and ANS regulation warrant further investigation.